Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Megan M. Dupuis, MD, shares the complex journey she traveled during medical training and how it brought her to the academic setting.

Bhagirathbhai Dholaria, MBBS, discusses additional 10-month follow-up data from the phase 1 TRIMM-2 trial of subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma.

Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.

Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.

Michael K. Gibson MD, PhD, discusses the importance of addressing unmet needs related to treatment for patients with gastrointestinal cancers.

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.

Dana B Cardin, MD, MSCI, discusses the rationale for exploring KRAS as a therapeutic target in pancreatic cancer.

Brian C. Grieb, MD, PhD, emphasizes the importance of investigating agents that target the MYC oncogene, as well as supportive cofactors, in colorectal cancer and other tumor types.

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors. 

Laura Goff, MD, discusses the investigation of adjuvant atezolizumab plus bevacizumab in hepatocellular carcinoma.

Mariana X. Byndloss, DVM, PhD, discusses the relationship between the gut microbiome and the risk of developing cancers such as colorectal cancer.

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

Laura Goff, MD, discusses the key takeaways from results of the phase 3 SWOG 1815 trial in newly diagnosed patients with advanced biliary tract cancers.

Michael K. Gibson MD, PhD, discusses current and emerging biomarkers in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma.

Andreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

With an overall 5-year survival rate of under 15% in patients with metastatic colorectal cancer, investigators have sought to parse mutational analyses to increase gains.

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.